695-12-5

应用筛选条件

关键词:'695-12-5'

显示 1-4 共 4 条结果关于 "695-12-5" 范围论文

Promoter hypermethylation-induced transcriptional down-regulation of the gene MYCT1 in laryngeal squamous cell carcinoma.

Min Yang et al.

BMC cancer, 12, 219-219 (2012-06-08)

MYCT1, previously named MTLC, is a novel candidate tumor suppressor gene. MYCT1 was cloned from laryngeal squamous cell cancer (LSCC) and has been found to be down-regulated in LSCC; however, the regulatory details have not been fully elucidated. Here, we

Secretory granule neuroendocrine protein 1 (SGNE1) genetic variation and glucose intolerance in severe childhood and adult obesity.

Nabila Bouatia-Naji et al.

BMC medical genetics, 8, 44-44 (2007-07-10)

7B2 is a regulator/activator of the prohormone convertase 2 which is involved in the processing of numerous neuropeptides, including insulin, glucagon and pro-opiomelanocortin. We have previously described a suggestive genetic linkage peak with childhood obesity on chr15q12-q14, where the 7B2

Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.

Alistair Murray et al.

The Cochrane database of systematic reviews, 8, CD000543-CD000543 (2020-08-14)

Oral 5-aminosalicylic acid (5-ASA) preparations were intended to avoid the adverse effects of sulfasalazine (SASP) while maintaining its therapeutic benefits. It was previously found that 5-ASA drugs in doses of at least 2 g/day were more effective than placebo but

Ursodeoxycholic acid for primary biliary cirrhosis.

Jelena S Rudic et al.

The Cochrane database of systematic reviews, 12, CD000551-CD000551 (2012-12-14)

Ursodeoxycholic acid is administered to patients with primary biliary cirrhosis, a chronic progressive inflammatory autoimmune-mediated liver disease with unknown aetiology. Despite its controversial effects, the U.S. Food and Drug Administration has approved its usage for primary biliary cirrhosis. To assess

1/1